Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future
Stockholm University, Faculty of Social Sciences, Aging Research Center (ARC), (together with KI). Karolinska Institutet, Sweden; University of Eastern Finland, Finland.
Show others and affiliations
2015 (English)In: Expert Review of Neurotherapeutics, ISSN 1473-7175, E-ISSN 1744-8360, Vol. 15, no 1, 83-105 p.Article, review/survey (Refereed) Published
Abstract [en]

Worldwide multidisciplinary translational research has led to a growing knowledge of the genetics and molecular pathogenesis of Alzheimer's disease (AD) indicating that pathophysiological brain alterations occur decades before clinical signs and symptoms of cognitive decline can be diagnosed. Consequently, therapeutic concepts and targets have been increasingly focused on early-stage illness before the onset of dementia; and distinct classes of compounds are now being tested in clinical trials. At present, there is a growing consensus that therapeutic progress in AD delaying disease progression would significantly decrease the expanding global burden. The evolving hypothesis- and evidence-based generation of new diagnostic research criteria for early-stage AD has positively impacted the development of clinical trial designs and the characterization of earlier and more specific target populations for trials in prodromal as well as in pre- and asymptomatic at-risk stages of AD.

Place, publisher, year, edition, pages
2015. Vol. 15, no 1, 83-105 p.
Keyword [en]
Alzheimer's disease, amyloid beta immunotherapy, bapineuzumab, biological markers, clinical trials, prevention, randomized controlled trials center dot systems biology, solanezumab, tau immunotherapy
National Category
Neurosciences Geriatrics
Identifiers
URN: urn:nbn:se:su:diva-113955DOI: 10.1586/14737175.2015.995637ISI: 000347802800008OAI: oai:DiVA.org:su-113955DiVA: diva2:789896
Note

AuthorCount:10;

Available from: 2015-02-20 Created: 2015-02-16 Last updated: 2017-12-04Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Aging Research Center (ARC), (together with KI)
In the same journal
Expert Review of Neurotherapeutics
NeurosciencesGeriatrics

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 38 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf